Mirum Pharmaceuticals shares are trading higher after the company announced it met its primary endpoint in the VISTAS Phase 2b study evaluating volixibat, an investigational treatment for cholestatic pruritus in patients with primary sclerosing cholangitis. Also, HC Wainwright & Co maintained its Buy rating and raised its price target on the stock from $150 to $175.